Mirikizumab

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights

Retrieved on: 
Wednesday, May 17, 2023
CD, Crohn's disease, TNF, Symantec Endpoint Protection, Takeda, IBD, JAK, SC, Mirikizumab, Eli Lilly and Company, JAK1, Adalimumab, Gastroenterology, Research, Ulcerative colitis, Eli Lilly, Inflammatory bowel disease, Infliximab, UC, AbbVie, Physician, CRL, BMS, FDA, Safety, RealTime, Vedolizumab, Pharmaceutical industry, Upadacitinib, Risankizumab, Pfizer

EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).

Key Points: 
  • EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).
  • According to Spherix's most recent RealTime Dynamix: Ulcerative Colitis (US) Q2 update, the majority of gastroenterologists are highly satisfied with the brand.
  • In fact, when pinned head-to-head against other leading UC brands on key agent attributes, Rinvoq has also made strong perceptual gains.
  • Spherix will continue to track the overall UC and CD markets and pulse gastroenterologists on their perceptions and intentions to use advanced therapies in their RealTime Dynamix services.

Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

Retrieved on: 
Friday, May 5, 2023
Takeda Pharmaceutical Company, Pressure, Injection, NASA RealWorld-InWorld Engineering Design Challenge, Risankizumab, EU, IV, TNF, Face, Takeda, JAK, SC, Mirikizumab, Eli Lilly and Company, Janssen, Ulcerative colitis, Traction, Patient, AbbVie, Physician, Need for Speed, CRL, BMS, Biosimilar, FDA, RealTime, Pharmaceutical industry, IL-23, Vedolizumab, Pfizer, Upadacitinib, Ustekinumab, UC

EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.

Key Points: 
  • EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab).
  • The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.
  • In the race to capture second-line UC patients, Janssen's Stelara (approved for UC in 2019) is currently favored by physicians.
  • Spherix will be monitoring the potential Entyvio SC US launch and the evolving UC market through its RealTime Dynamix™ advisory service.

Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen's Respective IL-23 Entries, According to Spherix Global Insights

Retrieved on: 
Friday, March 24, 2023
NASA RealWorld-InWorld Engineering Design Challenge, Crohn's disease, TNF, IBD, JAK, Mirikizumab, Janssen, Gastroenterology, Launch, Psoriasis, Eli Lilly, Inflammatory bowel disease, Lilly, AbbVie, Ulcerative colitis, Patient, VARSITY, FDA, RealTime, Pharmaceutical industry, UC, Risankizumab

EXTON, Pa., March 24, 2023 /PRNewswire/ -- In 2021, Eli Lilly ("Lilly") announced it would forego pursuing a psoriasis indication for its IL-23 inhibitor mirikizumab, strategically focusing instead on the inflammatory bowel disease (IBD) market. The decision created an opportunity to deliver the first indicated IL-23 inhibitor to the Ulcerative Colitis (UC) market. With an anticipated FDA decision just days away, the market is set to test how Lilly's decision will pay off should mirikizumab be approved.

Key Points: 
  • The decision created an opportunity to deliver the first indicated IL-23 inhibitor to the Ulcerative Colitis (UC) market.
  • With an anticipated FDA decision just days away, the market is set to test how Lilly's decision will pay off should mirikizumab be approved.
  • Spherix further found the prominence of the IL-23 class has been bolstered in general through its use in adjacent immunology indications (e.g.
  • Spherix will track mirikizumab performance through the first 18 months post approval through its Launch Dynamix™ service.

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

Retrieved on: 
Wednesday, November 30, 2022
MOA, Adalimumab, Need for Speed, Dermatology, Gastroenterology, TNF, Infliximab, AbbVie, Rheumatology, NASA RealWorld-InWorld Engineering Design Challenge, Ustekinumab, Patient, Neurology, BMS, IBD, Face, Janssen, Receptor modulator, Eli Lilly and Company, Ophthalmology, Ulcerative colitis, Mirikizumab, Vedolizumab, Inflammatory bowel disease, Crohn's disease, Pfizer, Nephrology, FDA, Pharmaceutical industry, Risankizumab, Upadacitinib, Ozanimod, UC, Takeda

EXTON, Pa., Nov. 30, 2022 /PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated with a biologic or small molecule are on their first-line advanced systemic therapy. Over the past eighteen months, the US inflammatory bowel disease (IBD) market has become increasingly competitive with the market entry of BMS' Zeposia and AbbVie's Rinvoq for the treatment of UC and AbbVie's Skyrizi in CD, which have had material changes to new start IBD treatment patterns.

Key Points: 
  • Spherix Global Insights ("Spherix") has been tracking the newly initiated IBD patient segment for the past five years via their RealWorld Dynamix service .
  • When specifically examining UC new starts, Zeposia, a first-in-class S1P receptor modulator, has made substantial inroads as a pre-biologic option, capturing a sizeable portion of first-line patients.
  • Unsurprisingly, the most prominent driver behind Zeposia use is the brand's oral administration, followed by the perceived efficacy and unique MOA.
  • Crohn's disease new start patterns have also been altered by the newest CD market entrant, Skyrizi.

Ulcerative Colitis Market Forecasts, Epidemiology & Pipeline Analysis 2022-2027: Focus on 8 Major Markets - United States, France, Germany, Italy, Spain, United Kingdom, China, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Biotechnology, Pharmaceutical, Health, AbbVie, NDA, Inflammatory bowel disease, UC, Safety, Mirikizumab, Research, Warfarin necrosis, Therapy, Filgotinib, Awareness, US Foods, Ulcerative colitis, Man, Galápagos Islands, Allergan, Novartis, USFDA, Disease management, Pfizer, Investment, Disease, David Berry (inventor), Takeda Pharmaceutical Company, Prevalence, FDA, CAGR, Johnson & Johnson, Knowledge, Clinical trial, Woman, Acquisition, Growth, Industry, Patient, Pharmaceutical industry, Dietary supplement, Fine chemical, Health insurance, Adalimumab, Upadacitinib, Proctitis, Epidemiology, Ulcer, Phase

The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries.

Key Points: 
  • The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries.
  • The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.
  • The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market.
  • Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis.